Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors
BOSTON, July 19, 2021 (World NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a medical stage biopharmaceutical corporation focused on developing medicine that meaningfully boost the lives of clients with rare cardiopulmonary disorder, these days declared the appointment of Allison Dorval, chief monetary officer of Voyager Therapeutics, Inc. (“Voyager”), as a member of Aerovate’s Board of Administrators.
“The addition of Allison’s company finance and broad operating expertise to our Board of Directors will serve Aerovate well as we look for to produce and commercialize AV-101, our novel dry powder inhaled formulation of the drug imatinib, for the procedure of pulmonary arterial hypertension, also acknowledged as PAH,” said Timothy Noyes, main executive officer of Aerovate. “We are thrilled to welcome her to Aerovate and to profit from her deep expertise, which includes offering money stewardship for publicly traded corporations.”
Ms. Dorval at present serves as main economic officer and principal finance and accounting officer at Voyager Therapeutics, and is a member of the Board of Directors of Puma Biotechnology, Inc. She has around 20 a long time of company finance, accounting and working experience, together with 14 yrs of daily life sciences govt finance experience. Prior to Voyager, Ms. Dorval served as vice president, controller, at Juniper Pharmaceuticals, Inc., and as chief monetary officer at Insulet Company, where by she led fiscal setting up, reporting and accounting. Earlier, Ms. Dorval held company finance positions with iBasis, Inc. and Digitas Inc. Ms. Dorval is a licensed public accountant and began her profession in public accounting at PricewaterhouseCoopers LLP, wherever she held positions of escalating obligation and scope. Ms. Dorval attained a Bachelor of Science in Enterprise Administration from the University of Vermont.
“Joining the Aerovate Board of Administrators provides a exclusive opportunity to lead to the enhancement of a novel technique to managing pulmonary arterial hypertension,” commented Ms. Dorval. “People struggling from PAH encounter a very poor prognosis, irrespective of the availability of many accredited therapies. I am thrilled about aiding Aerovate produce a probable new procedure selection for these underserved people.”
About Aerovate Therapeutics, Inc.
Aerovate is a medical stage biopharmaceutical enterprise focused on establishing medication that meaningfully increase the life of sufferers with exceptional cardiopulmonary sickness. Aerovate’s initial emphasis is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the cure of pulmonary arterial hypertension, or PAH.
Forward-Looking Statements
This push launch contains ahead-wanting statements within just the indicating of the Non-public Securities Litigation Reform Act of 1995, as amended, together with, with no limitation, convey or implied statements concerning the advancement of our clinical programs, our expectations of the therapeutic advantages similar thereto, and our advancement as a enterprise and the predicted contribution of the associates of our board of administrators to our functions and progress. The words and phrases “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and comparable expressions are supposed to discover forward-wanting statements, even though not all forward-on the lookout statements comprise these figuring out phrases.
Any forward-wanting statements in this press launch are centered on management’s latest anticipations and beliefs and are topic to a amount of risks, uncertainties and essential factors that may possibly cause true gatherings or success to differ materially from these expressed or implied by any forward-on the lookout statements contained in this press release, like, with no limitation, individuals pitfalls and uncertainties relevant to the progression of our medical method for AV-101, the envisioned effect and contribution of our Board of Administrators and executives to our company, and other threats recognized in our filings with the Securities and Exchange Commission (“SEC”), together with our Registration Assertion on Form S-1, and subsequent filings with the SEC. We caution you not to location undue reliance on any forward-wanting statements, which converse only as of the date they are built. We disclaim any obligation to publicly update or revise any this kind of statements to mirror any improve in expectations or in situations, problems or conditions on which any these statements may perhaps be based mostly, or that may perhaps impact the probability that real benefits will differ from those people established forth in the ahead-seeking statements. Any ahead-wanting statements contained in this press release characterize our views only as of the date hereof and ought to not be relied upon as symbolizing its views as of any subsequent day.
Get hold of: Speak to: Julio Cantre [email protected] 202.930.4762